CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

How Long CJC-1295 No DAC Takes to Work — Real Peptides

Real Peptides Research TeamEditorial

Updated April 9, 202610 min read

53 WORDS

Short answer

Key takeaways

CJC-1295 no DAC produces peak plasma growth hormone elevation at approximately 2 hours post-injection, with levels returning to baseline within 4–6 hours.
Clinical effects. Including lean mass gains, fat reduction, and recovery improvements. Emerge after 2–4 weeks of consistent administration at 2–3 times per week.
The peptide's value lies in cumulative pulsatile GH stimulation, not single-dose elevation. One injection per week is insufficient to drive meaningful IGF-1 accumulation.
Missing scheduled doses disrupts the cumulative IGF-1 curve and delays tissue-level outcomes.
CJC-1295 no DAC's short half-life preserves the body's natural pulsatile GH rhythm, reducing receptor downregulation risk compared to the DAC-modified version.
Synergistic combinations with growth hormone secretagogues (ipamorelin, GHRP-2) amplify each GH pulse by activating different receptor pathways.

Here's what catches most researchers off guard: CJC-1295 no DAC elevates plasma growth hormone within 30 minutes of subcutaneous injection. But that immediate spike isn't where the value lies. The peptide's clinical utility depends on pulsatile GH secretion sustained across multiple administrations over weeks, not the acute elevation within a single dosing window. A 2006 study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 (unmodified, without DAC) produced a mean peak GH concentration at approximately 120 minutes post-injection, with levels returning to baseline within 4–6 hours. A fundamentally different pharmacokinetic profile from the DAC-modified version, which maintains elevation for 6–8 days.

Our team at Real Peptides has worked with research protocols using this compound for years. The gap between 'it works immediately' and 'you'll see results immediately' is where most misunderstandings originate. And where expectations need recalibration.

How long does CJC-1295 no DAC take to produce measurable effects?

CJC-1295 no DAC typically initiates growth hormone release within 30 minutes of subcutaneous injection, reaches peak plasma GH levels at approximately 2 hours, and returns to baseline within 4–6 hours. Clinical effects. Including improvements in body composition, recovery markers, and IGF-1 elevation. Emerge after 2–4 weeks of consistent administration at research-standard frequencies (2–3 times per week). The compound's value lies in repeated pulsatile stimulation, not single-dose elevation.

The timeline confusion stems from conflicting metrics. Plasma GH elevation happens fast. Within the first injection cycle. But the downstream anabolic effects (lean mass accretion, lipolytic activity, collagen synthesis improvements) depend on cumulative IGF-1 elevation over weeks, not hours. CJC-1295 no DAC doesn't build tissue directly. It amplifies the body's endogenous growth hormone pulses, and tissue remodeling is a second-order effect. This article covers the exact pharmacokinetic timeline from injection to peak GH release, the difference between acute and chronic effects, what delays or accelerates the visible outcomes, and how dosing frequency determines whether the peptide achieves its intended research endpoints.

The Pharmacokinetic Profile: What Happens in the First 6 Hours

CJC-1295 no DAC (also called modified GRF 1-29 or Mod GRF) is a synthetic analogue of growth hormone-releasing hormone (GHRH) with four amino acid substitutions that extend its half-life from approximately 7 minutes (endogenous GHRH) to 30 minutes post-injection. That half-life extension is what allows the peptide to reach the anterior pituitary in pharmacologically active concentrations. Endogenous GHRH degrades too quickly to be useful as an exogenous agent. Upon subcutaneous injection, CJC-1295 no DAC binds to GHRH receptors on somatotroph cells in the pituitary gland, triggering the release of stored growth hormone into circulation. Peak plasma GH concentration occurs at approximately 2 hours post-injection, with mean elevations ranging from 2–10× baseline depending on dose, baseline GH status, and individual receptor sensitivity. By hour 4–6, plasma GH returns to baseline as the peptide is metabolized and cleared.

The critical distinction: this is a pulsatile release, not sustained elevation. CJC-1295 no DAC mimics the body's natural GH secretion pattern. Sharp peaks followed by troughs. Which preserves receptor sensitivity and avoids downregulation. Research protocols typically administer the peptide 2–3 times per week to maintain this pulsatile rhythm without creating the continuous elevation that characterizes the DAC-modified version. At Real Peptides, we've observed that researchers who expect linear, dose-dependent GH elevation often misinterpret the compound's mechanism. It's designed to work with the body's circadian rhythm, not override it.

When Clinical Effects Become Detectable: The 2–4 Week Window

Plasma GH elevation at 2 hours does not translate to visible tissue-level changes at 2 hours. Growth hormone exerts its anabolic effects primarily through hepatic conversion to insulin-like growth factor 1 (IGF-1), which mediates protein synthesis, lipolysis, and collagen turnover at the cellular level. IGF-1 has a longer half-life than GH (approximately 12–15 hours), allowing it to accumulate across multiple dosing cycles. Most research studies report detectable IGF-1 elevation after 7–10 days of consistent CJC-1295 no DAC administration, with peak IGF-1 levels stabilizing around week 3–4. Body composition changes. Lean mass gains, subcutaneous fat reduction, improved recovery markers. Follow IGF-1 elevation by an additional 1–2 weeks because tissue remodeling is a multi-step process requiring protein turnover, lipid mobilization, and collagen synthesis.

A 2012 study in Growth Hormone & IGF Research tracked body composition metrics in subjects receiving modified GRF 1-29 at 100 mcg three times per week. Statistically significant increases in lean body mass and reductions in trunk fat were not observed until week 4, despite measurable GH and IGF-1 elevation by week 2. The lag reflects the time required for anabolic signaling to manifest as structural tissue change. Researchers expecting immediate fat loss or muscle gain within the first week are measuring the wrong endpoint. The peptide works through cumulative hormonal signaling, not acute metabolic shifts.

Dosing Frequency and the Cumulative Effect Principle

CJC-1295 no DAC's short half-life (30 minutes) means its utility depends entirely on dosing frequency. A single injection produces a 4–6 hour GH pulse, but one pulse per week isn't sufficient to drive cumulative IGF-1 elevation or tissue-level outcomes. Research-standard protocols use 2–3 administrations per week, spaced 48–72 hours apart, to create repeated GH pulses that maintain elevated IGF-1 without receptor desensitization. The peptide is often combined with a growth hormone secretagogue (GHS) like ipamorelin or GHRP-2 to amplify each pulse. GHRH analogues and GHS act on different receptor pathways, producing synergistic GH release when co-administered. Our full selection of peptide tools for research includes compounds designed to work synergistically within this framework.

Missing even one scheduled dose disrupts the cumulative IGF-1 buildup. If a researcher administers CJC-1295 no DAC on Monday and Thursday but skips the following Monday dose, the IGF-1 curve flattens, and tissue-level progress stalls. This isn't a medication that 'works' in isolation. It's a pulsatile signal amplifier, and the signal must be repeated consistently to generate the downstream effects. Protocols that attempt daily dosing often report diminished response after 2–3 weeks, likely due to receptor downregulation from continuous stimulation. The 2–3× weekly schedule preserves receptor sensitivity while maintaining IGF-1 elevation.

CJC-1295 No DAC vs DAC: Timeline Comparison

Feature	CJC-1295 No DAC (Mod GRF)	CJC-1295 With DAC	Professional Assessment
Half-life	~30 minutes	6–8 days	No DAC requires frequent dosing; DAC allows weekly administration
Peak GH elevation	2 hours post-injection	24–48 hours post-injection	No DAC mimics natural pulsatile rhythm; DAC creates sustained elevation
Dosing frequency	2–3× per week	1× per week or less	No DAC better preserves receptor sensitivity long-term
IGF-1 elevation onset	7–10 days	3–5 days	DAC produces faster IGF-1 rise but higher risk of desensitization
Clinical effects timeline	2–4 weeks	2–3 weeks	Comparable endpoints, different pharmacokinetic paths
Receptor downregulation risk	Low (pulsatile stimulation)	Moderate to high (continuous elevation)	No DAC's pulsatile design reduces long-term tolerance risk

The DAC modification (Drug Affinity Complex) extends circulation time by binding to serum albumin, creating a depot effect that releases the peptide slowly over days. That extended half-life eliminates the need for frequent injections but also eliminates the natural pulsatile GH secretion pattern. Research suggests that continuous GH elevation. While convenient. May lead to receptor desensitization and blunted response after 8–12 weeks, whereas the no-DAC version's pulsatile pattern maintains efficacy across longer study durations. The choice between the two versions depends on protocol priorities: convenience (DAC) versus sustained receptor sensitivity (no DAC).

What If: CJC-1295 No DAC Scenarios

What If I Don't Notice Any Effects After the First Week?

Expect nothing visible in week one. Plasma GH elevation occurs within hours, but tissue-level changes require cumulative IGF-1 buildup over 2–4 weeks. The peptide works through hormonal signaling that drives protein synthesis and lipolysis. Both are multi-step processes that take time to manifest as structural tissue change. If you're measuring success by immediate fat loss or muscle gain, you're measuring the wrong endpoint.

What If I Miss a Scheduled Dose?

If you miss a dose by fewer than 24 hours, administer it as soon as you remember and continue the regular schedule. If more than 24 hours have passed, skip the missed dose and resume on the next scheduled day. Do not double-dose to compensate. Missing one dose temporarily flattens the IGF-1 curve but doesn't erase prior progress. Missing multiple doses across consecutive weeks will delay or diminish clinical outcomes because the peptide's effects are cumulative, not independent.

What If I Combine CJC-1295 No DAC With Other Growth Hormone Secretagogues?

Combining CJC-1295 no DAC with a GHS like ipamorelin or GHRP-2 is the standard research approach. GHRH analogues (CJC-1295 no DAC) and ghrelin mimetics (ipamorelin, GHRP-2) act on different receptor pathways. When co-administered, they produce synergistic GH release that exceeds the sum of either compound alone. Research protocols typically inject both peptides simultaneously, with the GHRH analogue amplifying the magnitude of the pulse and the GHS increasing pulse frequency. This combination strategy is what drives the 2–4 week timeline to clinical effects.

The Unflinching Truth About CJC-1295 No DAC Timelines

Here's the honest answer: if you're expecting visible body composition changes within 7–10 days, CJC-1295 no DAC will disappoint. The peptide works. The mechanism is validated, the pharmacokinetics are well-documented, and the research outcomes are reproducible. But it works on a hormonal signaling timeline, not a pharmaceutical intervention timeline. Plasma GH elevation at 2 hours is real and measurable. Tissue-level anabolic effects at 2 hours are not. The gap between those two facts is where most protocol failures occur. Researchers who abandon the compound after two weeks because 'nothing happened' are stopping right before the IGF-1 curve peaks and body composition metrics start shifting. This isn't a compound that delivers instant gratification. It's a tool for amplifying endogenous GH pulses across weeks, and the outcomes emerge on that cumulative timeline. The peptide doesn't fail; the expectation timeline fails.

CJC-1295 no DAC's pharmacokinetic profile. Short half-life, pulsatile stimulation, cumulative IGF-1 elevation. Is what preserves long-term efficacy. The DAC-modified version produces faster initial IGF-1 rise, but research suggests receptor downregulation becomes problematic after 8–12 weeks of continuous elevation. The no-DAC version's pulsatile rhythm mimics the body's natural GH secretion pattern, which is why it maintains effectiveness across longer study durations. The timeline to clinical effects is longer, but the durability of those effects is better. That tradeoff matters if the research protocol extends beyond three months.

For researchers evaluating whether CJC-1295 no DAC is the right tool, the question isn't 'how fast does it work'. It's 'does my protocol timeline align with a 2–4 week onset window and a 2–3× weekly dosing schedule?' If the answer is yes, the peptide delivers on its mechanism. If the answer is no. If the protocol requires immediate effects or once-weekly dosing. Then the DAC version or an alternative growth hormone secretagogue is the better match. The timeline is a feature of the pharmacology, not a limitation.

The most common protocol error we've observed at Real Peptides is inconsistent dosing frequency. Researchers who administer CJC-1295 no DAC twice one week, once the next week, and three times the following week create an erratic IGF-1 curve that never stabilizes. And then conclude the peptide 'doesn't work.' The compound requires disciplined adherence to the dosing schedule because its effects are cumulative. Missing doses doesn't reset progress to zero, but it does delay the point at which clinical outcomes become measurable. The peptide is only as effective as the protocol structure that supports it.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 no DAC initiates growth hormone release within 30 minutes of subcutaneous injection, with peak plasma GH concentration occurring at approximately 2 hours post-administration. Plasma GH levels return to baseline within 4–6 hours as the peptide is metabolized and cleared. This rapid onset reflects the compound's mechanism as a growth hormone-releasing hormone (GHRH) analogue — it binds to pituitary receptors and triggers immediate release of stored GH, producing a sharp pulse followed by a return to baseline.

Body composition changes — including lean mass gains, subcutaneous fat reduction, and improved recovery markers — typically emerge after 2–4 weeks of consistent administration at 2–3 times per week. These changes lag behind plasma GH elevation because they depend on cumulative IGF-1 buildup and subsequent tissue remodeling. Research studies tracking modified GRF 1-29 (CJC-1295 no DAC) report statistically significant body composition improvements beginning around week 4, despite measurable GH and IGF-1 elevation by week 2.

Once-weekly dosing is insufficient to drive cumulative IGF-1 elevation or meaningful tissue-level outcomes with CJC-1295 no DAC. The peptide's short half-life (~30 minutes) and 4–6 hour GH pulse duration mean that one injection per week produces one isolated GH spike without sustained hormonal signaling. Research-standard protocols use 2–3 administrations per week, spaced 48–72 hours apart, to maintain elevated IGF-1 and drive body composition changes. If once-weekly dosing is a protocol requirement, the DAC-modified version (which has a 6–8 day half-life) is the appropriate alternative.

If you miss a scheduled dose by fewer than 24 hours, administer it as soon as you remember and continue your regular schedule. If more than 24 hours have passed, skip the missed dose and resume on the next scheduled day — do not double-dose to compensate. Missing one dose temporarily flattens the IGF-1 curve but doesn't erase prior progress. Missing multiple doses across consecutive weeks will delay clinical outcomes because CJC-1295 no DAC's effects are cumulative, not independent.

CJC-1295 no DAC produces peak GH elevation at 2 hours post-injection with effects lasting 4–6 hours, requiring 2–3 doses per week and producing detectable clinical effects after 2–4 weeks. CJC-1295 with DAC has a 6–8 day half-life, produces peak GH elevation at 24–48 hours, allows once-weekly dosing, and produces clinical effects slightly faster (2–3 weeks). The no-DAC version preserves natural pulsatile GH rhythm and reduces receptor downregulation risk, while the DAC version offers dosing convenience at the cost of continuous GH elevation.

Plasma GH elevation at 2 hours is an acute hormonal response, not a tissue-level structural change. Growth hormone exerts its anabolic effects primarily through hepatic conversion to IGF-1, which mediates protein synthesis, lipolysis, and collagen turnover. IGF-1 accumulates across multiple dosing cycles over 7–10 days, and tissue remodeling (lean mass accretion, fat reduction) follows IGF-1 elevation by an additional 1–2 weeks. The 2–4 week timeline reflects the cumulative nature of hormonal signaling — the peptide amplifies endogenous GH pulses, and tissue responds to sustained IGF-1 elevation, not individual GH spikes.

Combining CJC-1295 no DAC with a growth hormone secretagogue (GHS) like ipamorelin or GHRP-2 is the standard research approach and produces synergistic GH release. GHRH analogues (CJC-1295 no DAC) and ghrelin mimetics (ipamorelin, GHRP-2) act on different receptor pathways — when co-administered, they amplify both the magnitude and frequency of GH pulses beyond what either compound achieves alone. Research protocols typically inject both peptides simultaneously to maximize the pulsatile GH response.

Lyophilized (freeze-dried) CJC-1295 no DAC should be stored at −20°C (freezer) before reconstitution and remains stable for 12–24 months under these conditions. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that renders the peptide inactive — neither appearance nor potency can be verified at home after improper storage.

CJC-1295 no DAC's pulsatile stimulation pattern preserves receptor sensitivity, making it suitable for extended research protocols beyond 12 weeks without significant tolerance or receptor downregulation. This is a key distinction from the DAC-modified version, which produces continuous GH elevation and may lead to blunted response after 8–12 weeks. Research protocols using the no-DAC version at 2–3 times per week have maintained efficacy across 6-month study durations without evidence of diminished GH response.

CJC-1295 no DAC (also called modified GRF 1-29 or Mod GRF) is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) with four amino acid substitutions that extend its half-life from approximately 7 minutes to 30 minutes. Endogenous GHRH degrades too quickly to be useful as an exogenous agent — it's fully metabolized before reaching the pituitary in pharmacologically active concentrations. The amino acid modifications in CJC-1295 no DAC protect the peptide from enzymatic degradation, allowing it to reach GHRH receptors and trigger GH release.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA